Prismasol 2 Potassium Solution
Calcium Chloride Hydrate 0.0257g · Magnesium Chloride Hydrate 0.0102g +5 more
Prescription medication · Combination
Vantive Korea Co., Ltd.
MFDS item code 201702025 · Approved 2017.04.20 · Insurance code 646601711
Dialysis and filtration treatment in patients with renal failure, drug poisoning, or a tendency to hyperkalemia
This product is used as a fluid substitute in blood filtration and hemodialysis for patients with renal failure, and it serves as a dialysis solution during continuous hemodialysis or continuous venovenous hemofiltration. Additionally, it can be utilized in the treatment of drug overdoses involving substances that can be dialyzed or filtered. This product is also effectively used in patients at risk of hyperkalemia. It offers assistance in a variety of kidney-related treatments and in managing drug intoxication.
The dose and rate of administration are determined according to the patient's blood electrolyte concentrations, acid-base balance, fluid balance, and overall clinical condition. The volume of replacement fluid and/or dialysate to be administered is determined according to the desired intensity of treatment (dose). This medicine should be prescribed and administered (dose, infusion rate, and cumulative volume) only by physicians experienced in critical care medicine and continuous renal replacement therapy. Replacement-fluid flow rate during hemofiltration and hemodiafiltration: Adults: 500 - 3000 ml/h Dialysate flow rate during continuous hemodialysis and continuous hemodiafiltration: Adults: 500 - 2500 ml/h The flow rate commonly used in adults is approximately 2000 - 2500 mL/h, corresponding to a daily replacement-fluid volume of approximately 48 - 60 L. For intravenous use and as replacement fluid for hemodialysis, administer into the extracorporeal circuit before (pre-dilution) or after (post-dilution) passage through the hemofilter or hemodiafilter.
Replacement-fluid flow rate during hemofiltration and hemodiafiltration: Children (adolescents 18 years of age or younger): 1000 - 2000 mL/h/1.73 m2 Replacement-fluid flow rate during hemofiltration and hemodiafiltration: Particularly in younger children (≤10 kg), a flow rate of up to 4000 mL/h/1.73 m2 may be required. The absolute flow rate (mL/h) in children and adolescents should generally not exceed the maximum flow rate for adults. Dialysate flow rate during continuous hemodialysis and continuous hemodiafiltration: Children (adolescents 18 years of age or younger): 1000 - 2000 mL/h/1.73 m2 Dialysate flow rate during continuous hemodialysis and continuous hemodiafiltration: Particularly in younger children (≤10 kg), a flow rate of up to 4000 mL/h/1.73 m2 may be required. The absolute flow rate (mL/h) in children and adolescents should generally not exceed the maximum flow rate for adults.
This product should not be used in certain patients. For example, it is contraindicated in patients with known allergies to this product, those with low serum potassium levels, patients with metabolic alkalosis, individuals with severe renal failure who do not improve with blood filtration in uremia, patients with insufficient arterial pressure during vascular access, and patients who are at high risk for bleeding while receiving systemic anticoagulation therapy. Caution is needed as adverse reactions may occur while using this product. Fluid imbalance, electrolyte disturbances, hyperglycemia, metabolic alkalosis or acidosis, hypotension, nausea and vomiting, and muscle cramps may occur. Adverse reactions related to hemodialysis have been reported. This product should be used under the supervision of an experienced physician in blood filtration or hemodialysis, and during treatment, serum potassium levels, hemodynamic status, fluid balance, electrolytes, and acid-base balance should be closely monitored. Phosphate levels should also be checked periodically, and inorganic phosphate supplementation should be provided in cases of hypophosphatemia. Diabetic patients should regularly check their blood sugar levels, and if hyperglycemia occurs, switching to a dextrose-free solution or additional measures may be necessary. Patients with fluid imbalance should be carefully monitored regarding their clinical status, and measures should be taken to restore normal fluid balance. Since this product contains potassium, there is a risk of hyperkalemia. If hyperkalemia occurs after treatment initiation, potassium sources should be checked, and the infusion rate should be reduced or discontinued if necessary. If hyperkalemia persists, potassium-free dialysis solutions can be used to promote potassium removal. Patients with corn allergies should not use this product, and if an allergic reaction is suspected, administration should be immediately stopped and appropriate treatment should be received. This product may interact with other medications during blood filtration or hemodialysis, so adjustments should be made considering changes in the concentration of the medications being treated. Caution should particularly be exercised when used in conjunction with sodium bicarbonate or citrates, as there is a risk of metabolic alkalosis or changes in calcium levels. Safety during pregnancy or lactation has not been established, so the benefits and risks should be carefully evaluated before use. In case of an overdose, fluid overload, electrolyte, and acid-base imbalances may occur, and in such cases, administration should be discontinued and appropriate interventions taken. No specific antidotes for overdose are available, so careful monitoring during treatment is essential. This product should only be used in an environment equipped with appropriate renal replacement therapy devices, and prior to use, the solution should be verified to be clear and free from discoloration or precipitate. The mixed solution should be prepared in a sterile manner and should be used immediately; any unused solution should be discarded. The solution may be warmed to 37 degrees Celsius, but it should not be heated in a microwave or with water; only dry heat methods should be used. Furthermore, this product should not be mixed with other medications, and compatibility should always be confirmed. When storing, it should be kept in a sealed container to prevent air or moisture from entering, and it is recommended to store in a cool place between 4 and 30 degrees Celsius. By storing in this manner, the effectiveness of the medication can be maintained, and degradation can be prevented.
Not everyone experiences these, and they can vary from person to person.
This product should be stored in a sealed container to prevent air or moisture infiltration, ideally in a cool place between 4 and 30 degrees Celsius. Storing in this way will help preserve the drug's efficacy and prevent degradation.
A slightly transparent yellow blood dialysis filtrate after mixing
5000 ml / pack
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Calcium Chloride Hydrate 0.0257g · Magnesium Chloride Hydrate 0.0102g +5 more
Prescription medication · Combination
Vantive Korea Co., Ltd.
Calcium Chloride Hydrate 0.0257g · Magnesium Chloride Hydrate 0.0102g +5 more
Prescription medication · Combination
Ventive Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.